Metastatic breast cancer advanced ovarian cancer, AIDS-related Kaposi's sarcoma.
Breast cancer/ovarian cancer: 50 mg/m2 IV once every 4 weeks. AIDS-Kaposi's sarcoma 20mg/m2 IV every 2-3 weeks for 2-3 months
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is thought to inhibit DNA-dependent RNA synthesis by forming a complex with DNA through intercalation with guanine residues and impairing the template activity of DNA. It also has some immunosuppressive and hypocalcaemic activities.
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; severe myelosuppression with resulting infection or bleeding may occur; cardiac function should be monitored regularly.
Myelosuppression [sometimes severe]; cardiac toxicity and congestive heart failure; triad of back pain; flushing; and chest tightness; increased appetite; dysphagia; GI haemorrhage; gastritis; stomatitis; nausea and vomiting; gingival bleeding; hemorrhoids; mele-na; diarrhea; abdominal pain; anorexia; and constipation; dry mouth; taste perversion; thirst; hiccups; or tooth caries; neuropathy; amnesia; anxiety; ataxia; confusion; emotional lability; hallucination; hyperkinesias; hypertonia; tremor; somnolence; seizures; alopecia; pigmentation of fingernails and toenails; severe local tissue damage in extravasation; fever; myalgia; hypocalcaemia; hypersensitivity reactions.
This long-circulating pegylated liposomal formulation of doxorubicin HCl that provides greater concentration of doxorubicin in Kaposi's sarcoma [KS] tumors than in normal skin. Pegylated liposomes contain surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol [MPEG] on the liposome surface creating a protective coating that reduces interactions between the lipid bilayer membrane and the plasma components. This allows the drug to circulate for prolonged periods in the blood stream.